NASDAQ:OMER

Omeros Stock Forecast, Price & News

$14.97
-0.03 (-0.20 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.68
$15.16
50-Day Range
$14.81
$19.13
52-Week Range
$9.25
$25.46
Volume293,959 shs
Average Volume690,159 shs
Market Capitalization$933.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
30 days | 90 days | 365 days | Advanced Chart
Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.


Omeros logo

About Omeros

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consist of PPAR? (OMS405) to treat opioid and nicotine addiction; PDE7 (OMS527) for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

492nd out of 2,102 stocks

Pharmaceutical Preparations Industry

239th out of 832 stocks

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Omeros (NASDAQ:OMER) Frequently Asked Questions

Is Omeros a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Omeros stock.
View analyst ratings for Omeros
or view top-rated stocks.

What stocks does MarketBeat like better than Omeros?

Wall Street analysts have given Omeros a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Omeros wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Omeros' next earnings date?

Omeros is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Omeros
.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) announced its earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.57). The biopharmaceutical company had revenue of $21.10 million for the quarter, compared to the consensus estimate of $21.96 million. The business's quarterly revenue was down 10.6% on a year-over-year basis.
View Omeros' earnings history
.

How has Omeros' stock been impacted by Coronavirus (COVID-19)?

Omeros' stock was trading at $15.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OMER shares have decreased by 0.5% and is now trading at $14.97.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OMER?

5 brokerages have issued 1-year price objectives for Omeros' shares. Their forecasts range from $12.00 to $32.00. On average, they expect Omeros' stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 53.6% from the stock's current price.
View analysts' price targets for Omeros
or view top-rated stocks among Wall Street analysts.

Who are Omeros' key executives?

Omeros' management team includes the following people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 62, Pay $813.81k)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 63, Pay $369.95k)
  • Mr. Peter B. Cancelmo J.D., VP, Gen. Counsel & Corp. Sec. (Age 42, Pay $307.91k)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 58)
  • Dr. George A. Gaitanaris M.D., Ph.D., Chief Scientific Officer & VP of Science (Age 64)
  • Mr. Peter W. Williams, VP of HR (Age 53)
  • Dr. J. Steven Whitaker, VP of Clinical Devel. & Chief Medical Officer (Age 65)
  • Dr. Catherine A. Melfi, Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems (Age 62)
  • Ms. Nadia Dac, Chief Commercial Officer (Age 51)

What is Gregory A. Demopulos' approval rating as Omeros' CEO?

17 employees have rated Omeros CEO Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among Omeros' employees.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Who are Omeros' major shareholders?

Omeros' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.12%), Geode Capital Management LLC (1.60%), Stifel Financial Corp (1.53%), Northern Trust Corp (1.11%), Cpwm LLC (1.07%) and Nuveen Asset Management LLC (0.80%). Company insiders that own Omeros stock include Gregory A Md Demopulos, Michael A Jacobsen and Thomas J Cable.
View institutional ownership trends for Omeros
.

Which institutional investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Empire Life Investments Inc., UBS Group AG, American Financial Group Inc., Nuveen Asset Management LLC, Northern Trust Corp, and State Board of Administration of Florida Retirement System. Company insiders that have sold Omeros company stock in the last year include Gregory A Md Demopulos, Michael A Jacobsen, and Thomas J Cable.
View insider buying and selling activity for Omeros
or view top insider-selling stocks.

Which institutional investors are buying Omeros stock?

OMER stock was bought by a variety of institutional investors in the last quarter, including Falcon Edge Capital LP, Federated Hermes Inc., Voloridge Investment Management LLC, Geode Capital Management LLC, Brighton Jones LLC, Tudor Investment Corp Et Al, Barclays PLC, and Cubist Systematic Strategies LLC.
View insider buying and selling activity for Omeros
or or view top insider-buying stocks.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $14.97.

How much money does Omeros make?

Omeros has a market capitalization of $933.05 million and generates $73.81 million in revenue each year. The biopharmaceutical company earns $-138,060,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis.

How many employees does Omeros have?

Omeros employs 277 workers across the globe.

What is Omeros' official website?

The official website for Omeros is www.omeros.com.

Where are Omeros' headquarters?

Omeros is headquartered at 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.